FDA improperly denied Ranbaxy, Ivax rights to exclusivity

Share this content:
A federal judge ruled the FDA improperly denied generic drugmakers Ranbaxy and Ivax rights to 180 days of marketing exclusivity for generic forms of Merck's cholesterol-lowering drug Zocor (simvastatin). He threw out the FDA's decision to grant Merck's request to delist two patents.
Share this content:
Scroll down to see the next article